3,675 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, HoldingsChannel reports. The fund acquired 3,675 shares of the biopharmaceutical company’s stock, valued at approximately $339,000.

Several other institutional investors also recently modified their holdings of the company. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC raised its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GILD shares. Oppenheimer upped their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 1.1 %

Shares of GILD opened at $107.89 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a market cap of $134.36 billion, a price-to-earnings ratio of 291.59, a PEG ratio of 0.71 and a beta of 0.21. The business’s fifty day moving average is $104.35 and its 200-day moving average is $94.36.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.93%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.